14 July 2023
\n \n \n \nSeveral of our research groups have been accredited by the Laboratory Efficiency Assessment Framework (LEAF).
\n \n\n \n \n28 June 2023
\n \n \n \nClinical scientists in Oxford have presented a new method of imaging of the retina that overcomes many of the drawbacks of the current standard way of diagnosing and monitoring retinal diseases like age-related macular degeneration (AMD).
\n \n\n \n \n28 June 2023
\n \n \n \nIn the midst of a global opioid epidemic, a team of scientists is exploring natural killer (NK) cells as an alternative treatment for neuropathic pain.
\n \n\n \n \n21 June 2023
\n \n \n \nA ground-breaking experimental medicine programme that will enable researchers to more rapidly screen potential drugs in people with motor neuron disease (MND, also known as ALS), is announced today on Global MND Awareness Day.
\n \n\n \n \n15 June 2023
\n \n \n \n\n \n \n12 June 2023
\n \n \n \nBeacon Therapeutics, a pioneering new biotech company, has launched with a mission to restore and improve the vision of patients with retinal diseases. The company is one of the most ambitious spinouts the University has been involved in to date, starting out with an impressive \u00a396 million ($118.5m) in funding, the biggest launch for any company including an Oxford spin-out programme.
\n \n\n \n \n26 May 2023
\n \n \n \nThe University of Oxford and Selvita (WSE: SLV), one of the largest contract research organisations in Europe, are collaborating on drug discovery in the area of Parkinson's disease
\n \n\n \n \n18 May 2023
\n \n \n \nProfessor Espie is one of eight Oxford researchers to become Fellows of the Academy of Medical Sciences.
\n \n\n \n \n2 May 2023
\n \n \n \nTwo papers by early career researchers in our Oxford Epilepsy Research Group have been highlighted recently.
\n \n\n \n \n26 April 2023
\n \n \n \nA new study has shown the need for more widespread screening for frailty in unplanned admissions to hospitals to better inform the care received by patients.
\n \n\n \n \n20 April 2023
\n \n \n \nAnd the certainty of evidence supporting its use is low, say researchers
\n \n\n \n \n14 March 2023
\n \n \n \nThe new Cohort Catalogue will facilitate discovery of over 60 neurodegeneration research cohorts from 17 countries across Europe
\n \n\n \n \n9 March 2023
\n \n \n \nThe British Neuroscience Association Scholars Programme was launched in 2021 with a view to improving equality, diversity and inclusion in neuroscience.
\n \n\n \n \n7 March 2023
\n \n \n \nThe MRC Brain Network Dynamics Unit has received funding for a multi-year research partnership designed to advance the understanding of early changes to the operations of brain circuits in Alzheimer's disease.
\n \n\n \n \n6 March 2023
\n \n \n \nOn 21 February, Robert MacLaren organised a one-day ophthalmology conference in Kyiv together with Dr Andrii Ruban, President of the Ukrainian Vitreoretinal Society.
\n \n\n \n \n31 January 2023
\n \n \n \nThe first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.
\n \n\n \n \n3 January 2023
\n \n \n \nNMDAR-antibody encephalitis is an autoimmune brain condition caused by patient\u2019s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.
\n \n\n \n \n15 December 2022
\n \n \n \nFrom 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.
\n \n\n \n \n21 November 2022
\n \n \n \n\n \n \n14 November 2022
\n \n \n \nNew research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.
\n \n\n \n \n